A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521216-19-00

Acronym

NBI-1117568-SCZ3032

Enrollment

151

Registered

2025-11-21

Start date

2025-12-10

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Occurrence of AEs during the Open-Label Treatment Period

Interventions

DRUGNBI-1117568

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Occurrence of AEs during the Open-Label Treatment Period	—

Countries

Bulgaria, Hungary, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026